Showing 1 – 20 of 389
Relevance | Newest | Oldest |
  • Anti–β-Amyloid Treatment May Need to Be Started Early

    Abstract Full Text
    JAMA. 2015; 314(12):1217-1217. doi: 10.1001/jama.2015.11782
  • Researchers Probe the Aging Brain in Health and Disease

    Abstract Full Text
    JAMA. 2014; 311(3):231-232. doi: 10.1001/jama.2013.284609
  • Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial

    Abstract Full Text
    free access is active quiz
    JAMA. 2016; 315(15):1580-1590. doi: 10.1001/jama.2016.3608

    This 2-stage randomized clinical trial compared lipid-lowering efficacy of 2 nonstatin therapies, ezetimibe and evolocumab, among patients with uncontrolled low-density lipoprotein cholesterol levels and intolerance to 2 or more statins.

  • Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus: The AleCardio Randomized Clinical Trial

    Abstract Full Text
    free access
    JAMA. 2014; 311(15):1515-1525. doi: 10.1001/jama.2014.3321

    Lincoff and coauthors determine whether addition of aleglitazar to standard medical therapy reduces cardiovascular morbidity and mortality among 7226 patients with type 2 diabetes mellitus (T2D) and a recent acute coronary syndrome (ACS).

  • Effects of Lowering Elevated LDL Cholesterol on the Cardiovascular Risk of Lipoprotein(a)

    Abstract Full Text
    JAMA. 1995; 274(22):1771-1774. doi: 10.1001/jama.1995.03530220037029
  • Prevalence of Amyloid PET Positivity in Dementia Syndromes: A Meta-analysis

    Abstract Full Text
    free access
    JAMA. 2015; 313(19):1939-1950. doi: 10.1001/jama.2015.4669

    This participant-level meta-analysis estimates the prevalence of PET scan–measured amyloid in Alzheimer disease participants and its associations with age, sex, education, cognitive function, and APOE genotype.

  • Claims of Sex Differences: An Empirical Assessment in Genetic Associations

    Abstract Full Text
    JAMA. 2007; 298(8):880-893. doi: 10.1001/jama.298.8.880
  • Ten-Year Follow-up After Initiation of Statin Therapy in Children With Familial Hypercholesterolemia

    Abstract Full Text
    free access
    JAMA. 2014; 312(10):1055-1057. doi: 10.1001/jama.2014.8892
  • Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis

    Abstract Full Text
    free access
    JAMA. 2015; 313(19):1924-1938. doi: 10.1001/jama.2015.4668

    This meta-analysis explores the association of amyloid pathology with age, APOE genotype, sex, education, and presence of cognitive impairment among persons without dementia.

  • IOM Addresses Ongoing Effects of Blast Injury on Soldiers

    Abstract Full Text
    JAMA. 2014; 311(11):1098-1099. doi: 10.1001/jama.2014.1993
  • JAMA November 11, 2009

    Figure 3: Hazard Ratios for Coronary Heart Disease Across Fifths of Usual Lipids or Apolipoproteins

    Analyses were based on 91 307 participants (involving 4499 cases) from 22 studies. Regression analyses were stratified, where appropriate, by sex and trial group and adjusted for age, systolic blood pressure, smoking status, history of diabetes mellitus, and body mass index; furthermore, analyses of non–HDL-C were adjusted for HDL-C and loge triglyceride, analyses of apolipoprotein B (apo B) were adjusted for apolipoprotein AI (apo AI) and loge triglyceride, analyses of HDL-C were adjusted for non–HDL-C and loge triglyceride, and analyses of apo AI were adjusted for apo B and loge triglyceride. Studies with fewer than 10 cases were excluded from analysis. Sizes of data markers are proportional to the inverse of the variance of the hazard ratios. Referent groups are lowest fifths. Lines are fitted by first-degree fractional polynomial regression of log hazard ratios on mean SD score. Error bars indicate 95% confidence intervals. The y-axis is shown on a log scale. The x-axis is shown on a Z-transformed scale.
  • Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes: A Randomized Controlled Trial

    Abstract Full Text
    free access
    JAMA. 2003; 290(17):2292-2300. doi: 10.1001/jama.290.17.2292
  • Plasma Lipids, Genetic Variants Near APOA1 , and the Risk of Infantile Hypertrophic Pyloric Stenosis

    Abstract Full Text
    free access
    JAMA. 2013; 310(7):714-721. doi: 10.1001/jama.2013.242978

    To investigate genetic risk variants for infantile hypertrophic pyloric stenosis, Feenstra and coauthors searched the genome for genetic associations and then validated findings in 3 independent case-control sample sets that included a total of 2664 cases and 4686 controls.

  • Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease

    Abstract Full Text
    free access
    JAMA. 2017; 317(9):937-946. doi: 10.1001/jama.2017.0972

    This cross-sectional study examines whether rare and common variants in the lipoprotein lipase gene are associated with early-onset coronary artery disease.

  • Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease: The TEAM-AD VA Cooperative Randomized Trial

    Abstract Full Text
    free access has multimedia
    JAMA. 2014; 311(1):33-44. doi: 10.1001/jama.2013.282834

    In a double-blind, placebo-controlled, parallel-group, randomized clinical trial with 613 patients, Dysken and coauthors investigated the use of vitamin E (alpha tocopherol), memantine, and a combination to slow progression of mild to moderate Alzheimer disease (AD). In an Editorial, Evans and coauthors discuss the best features in trials of AD therapy and a balance between treatment and prevention.

  • Molecular Findings Among Patients Referred for Clinical Whole-Exome Sequencing

    Abstract Full Text
    free access is active quiz
    JAMA. 2014; 312(18):1870-1879. doi: 10.1001/jama.2014.14601

    This observation trial reports that whole-exome sequencing provides a potential molecular diagnosis for patients referred for evaluation of suspected genetic conditions, including detection of rare genetic events and new mutations, contributing to disease.

  • Effect of a Dietary Portfolio of Cholesterol-Lowering Foods Given at 2 Levels of Intensity of Dietary Advice on Serum Lipids in Hyperlipidemia: A Randomized Controlled Trial

    Abstract Full Text
    free access has multimedia
    JAMA. 2011; 306(8):831-839. doi: 10.1001/jama.2011.1202
  • Alzheimer Gene APOE ε4 Linked to Brain Development in Infants

    Abstract Full Text
    JAMA. 2014; 311(3):298-299. doi: 10.1001/jama.2013.285400
  • JAMA January 21, 2009

    Figure: Example of a Receiver Operating Characteristic (ROC) Curve for Cardiovascular Risk Related to APOE

    A, Example of an ROC curve for a test that performs no better than chance. B, Example of an ROC curve for a test with perfect predictive ability (sensitivity = 100%; specificity = 100%). C, ROC curves for cardiovascular disease calculated using PROCAM (Prospective Cardiovascular Munster study) risk score plus APOE genotype. Based on 2451 men (of 3012 eligible) who had complete data for PROCAM and APOE genotyping. APOE genotype was fitted as a class variable with 3 categories 33, 22/23, and 34/44. Factors included age, body mass index, total cholesterol, triglycerides, systolic blood pressure, and family history. Other factors in PROCAM were not measured in all men. For the PROCAM score, the ROC value (95% confidence interval) was 0.65 (0.61-0.70), with a detection rate of 11.7% for a false-positive rate of 5.0%. In univariate analysis, APOE genotype was significant at P = .01. In multivariate analysis, the area under the curve increased to 0.67 (0.63-0.71) (detection rate,14.0%), but this improvement was not significant (P = .11). Panel C data based on Humphries et al.
  • Bariatric Surgery and Long-term Cardiovascular Events

    Abstract Full Text
    free access
    JAMA. 2012; 307(1):56-65. doi: 10.1001/jama.2011.1914